Who owns Verona Pharma plc, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
JANUS HENDERSON GROUP PLC: 1.2% · 1,010,564 shares
Pentwater Capital Management LP: 0.0% · 0 shares — Matthew Halbower: 0.0% · 0 shares
6 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Verona Pharma plc.
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Verona Pharma plc they hold. Together these 385 managers report 15.84% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| Pentwater Capital Management LP | $566M | 5,300,000 | 3.16% | 0.78% | September 30, 2025 |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | $457M | 4,283,462 | 13.68% | 0.63% | September 30, 2025 |
383 more institutional holders behind a free account
See every manager reporting Verona Pharma plc, how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 172 funds hold 2.55% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| BlackRock Event Driven Equity Fund | $256M | 5.26% | 0.36% | August 29, 2025 |
| T. Rowe Price Health Sciences Fund, Inc. | $128M | 1.14% | 0.20% | June 30, 2025 |
170 more funds behind a free account
See every fund holding Verona Pharma plc and what share of its net assets the position represents.
Sign up freeLoading...
